Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors.

Doolittle ND, Muldoon LL, Brummett RE, Tyson RM, Lacy C, Bubalo JS, Kraemer DF, Heinrich MC, Henry JA, Neuwelt EA.

Clin Cancer Res. 2001 Mar;7(3):493-500.

2.

Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity.

Muldoon LL, Pagel MA, Kroll RA, Brummett RE, Doolittle ND, Zuhowski EG, Egorin MJ, Neuwelt EA.

Clin Cancer Res. 2000 Jan;6(1):309-15.

3.

First evidence of otoprotection against carboplatin-induced hearing loss with a two-compartment system in patients with central nervous system malignancy using sodium thiosulfate.

Neuwelt EA, Brummett RE, Doolittle ND, Muldoon LL, Kroll RA, Pagel MA, Dojan R, Church V, Remsen LG, Bubalo JS.

J Pharmacol Exp Ther. 1998 Jul;286(1):77-84.

PMID:
9655844
4.

Ototoxicity resulting from combined administration of cisplatin and gentamicin.

Riggs LC, Brummett RE, Guitjens SK, Matz GJ.

Laryngoscope. 1996 Apr;106(4):401-6.

PMID:
8614212
5.

In vitro and animal studies of sodium thiosulfate as a potential chemoprotectant against carboplatin-induced ototoxicity.

Neuwelt EA, Brummett RE, Remsen LG, Kroll RA, Pagel MA, McCormick CI, Guitjens S, Muldoon LL.

Cancer Res. 1996 Feb 15;56(4):706-9.

6.

Safety of silver oxide-impregnated silastic tympanostomy tubes.

Chole RA, Brummett RE, Tinling SP.

Am J Otol. 1995 Nov;16(6):722-4.

PMID:
8572133
7.

Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms.

Williams PC, Henner WD, Roman-Goldstein S, Dahlborg SA, Brummett RE, Tableman M, Dana BW, Neuwelt EA.

Neurosurgery. 1995 Jul;37(1):17-27; discussion 27-8.

PMID:
8587686
8.

Effect of otologic drill noise on ABR thresholds in a guinea pig model.

Suits GW, Brummett RE, Nunley J.

Otolaryngol Head Neck Surg. 1993 Oct;109(4):660-7.

PMID:
8233501
9.

Ototoxicity of vancomycin and analogues.

Brummett RE.

Otolaryngol Clin North Am. 1993 Oct;26(5):821-8. Review.

PMID:
8233491
10.

Ototoxic liability of erythromycin and analogues.

Brummett RE.

Otolaryngol Clin North Am. 1993 Oct;26(5):811-9. Review.

PMID:
8233490
11.

Quantitative relationships of the interaction between sound and kanamycin.

Brummett RE, Fox KE, Kempton JB.

Arch Otolaryngol Head Neck Surg. 1992 May;118(5):498-500.

PMID:
1571121
12.

Steroids and rhinoplasty. A double-blind study.

Hoffmann DF, Cook TA, Quatela VC, Wang TD, Brownrigg PJ, Brummett RE.

Arch Otolaryngol Head Neck Surg. 1991 Sep;117(9):990-3; discussion 994.

PMID:
1910730
13.

The incidence of aminoglycoside antibiotic-induced hearing loss.

Brummett RE, Morrison RB.

Arch Otolaryngol Head Neck Surg. 1990 Apr;116(4):406-10.

PMID:
2317321
14.

Augmented gentamicin ototoxicity induced by vancomycin in guinea pigs.

Brummett RE, Fox KE, Jacobs F, Kempton JB, Stokes Z, Richmond AB.

Arch Otolaryngol Head Neck Surg. 1990 Jan;116(1):61-4.

PMID:
2294943
15.

Aminoglycoside-induced hearing loss in humans.

Brummett RE, Fox KE.

Antimicrob Agents Chemother. 1989 Jun;33(6):797-800. Review. No abstract available.

16.

Vancomycin- and erythromycin-induced hearing loss in humans.

Brummett RE, Fox KE.

Antimicrob Agents Chemother. 1989 Jun;33(6):791-6. Review. No abstract available.

17.

Potential hearing loss resulting from MR imaging.

Brummett RE, Talbot JM, Charuhas P.

Radiology. 1988 Nov;169(2):539-40.

PMID:
3175004
18.

The influence of tobramycin dosage regimens on nephrotoxicity, ototoxicity, and antibacterial efficacy in a rat model of subcutaneous abscess.

Wood CA, Norton DR, Kohlhepp SJ, Kohnen PW, Porter GA, Houghton DC, Brummett RE, Bennett WM, Gilbert DN.

J Infect Dis. 1988 Jul;158(1):13-22.

PMID:
3134490
19.

Effects of pentoxifylline on experimental skin flap survival.

Hodgson RS, Brummett RE, Cook TA.

Arch Otolaryngol Head Neck Surg. 1987 Sep;113(9):950-2.

PMID:
3606845
20.

Absence of ototoxicity of teichomycin A2 in guinea pigs.

Brummett RE, Fox KE, Warchol M, Himes D.

Antimicrob Agents Chemother. 1987 Apr;31(4):612-3.

21.

Wound healing and the Shaw scalpel.

Millay DJ, Cook TA, Brummett RE, Nelson EL, O'Neill PL.

Arch Otolaryngol Head Neck Surg. 1987 Mar;113(3):282-5.

PMID:
3814370
22.

Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients.

Bernstein JM, Gorse GJ, Linzmayer MI, Pegram PS, Levin RD, Brummett RE, Markowitz N, Saravolatz LD, Lorber RR.

Arch Intern Med. 1986 Dec;146(12):2329-34.

PMID:
3535719
23.

Ototoxicity of intraventricularly administered gentamicin in adult rabbits.

Hodges GR, Watanabe IS, Singer P, Rengachary S, Brummett RE, Reeves D, Justesen DR, Worley SE, Gephardt EP Jr.

Res Commun Chem Pathol Pharmacol. 1985 Dec;50(3):337-47.

PMID:
4081322
24.

Dissociation of maximum concentration of kanamycin in plasma and perilymph from ototoxic effect.

Davis RR, Brummett RE, Bendrick TW, Himes DL.

J Antimicrob Chemother. 1984 Sep;14(3):291-302.

PMID:
6490573
26.

Gillies' corner stitch revisited.

McQuown SA, Cook TA, Brummett RE, Trachy RE.

Arch Otolaryngol. 1984 Jul;110(7):450-3.

PMID:
6375646
27.

Detection of aminoglycoside ototoxicity by high-frequency auditory evaluation: selected case studies.

Fausti SA, Rappaport BZ, Schechter MA, Frey RH, Ward TT, Brummett RE.

Am J Otolaryngol. 1984 May-Jun;5(3):177-82.

PMID:
6742338
28.

Age related changes influencing the effects of drugs and other xenobiotics on sensorineural hearing.

Brummett RE, Jackson RT.

Pharmacol Ther. 1984;26(2):209-19. Review. No abstract available.

PMID:
6398449
29.

Lidocaine in the treatment of tinnitus aurium. A double-blind study.

Israel JM, Connelly JS, McTigue ST, Brummett RE, Brown J.

Arch Otolaryngol. 1982 Aug;108(8):471-3.

PMID:
7049137
30.

The ototoxic interaction of viomycin, capreomycin and polymyxin B with ethacrynic acid.

Davis RR, Brummett RE, Bendrick TW, Himes DL.

Acta Otolaryngol. 1982;93(1-6):211-7.

PMID:
6175163
31.

Effects of antibiotic-diuretic interactions in the guinea pig model of ototoxicity.

Brummett RE.

Rev Infect Dis. 1981 Nov-Dec;3 suppl:S216-23.

PMID:
7342284
32.

Comparative ototoxicity of bumetanide and furosemide when used in combination with kanamycin.

Brummett RE, Bendrick T, Himes D.

J Clin Pharmacol. 1981 Nov-Dec;21(11):628-36.

PMID:
7338574
33.

Ototoxicity resulting from the combined administration of potent diuretics and other agents.

Brummett RE.

Scand Audiol Suppl. 1981;14 Suppl:215-24. No abstract available.

PMID:
6949282
34.

Combined effects of noise and kanamycin. Cochlear pathology and pharmacology.

Brown JJ, Brummett RE, Fox KE, Bendrick TW.

Arch Otolaryngol. 1980 Dec;106(12):744-50.

PMID:
7436850
35.

Drug-induced ototoxicity.

Brummett RE.

Drugs. 1980 Jun;19(6):412-28. No abstract available.

PMID:
7389589
36.

A comparative study of the ototoxicity of gentamicin and gentamicin C1.

Fox KE, Brummett RE, Brown R, Himes D.

Arch Otolaryngol. 1980 Jan;106(1):44-9.

PMID:
7352894
37.

A system for evaluating auditory function from 8000--20 000 Hz.

Fausti SA, Frey RH, Erickson DA, Rappaport BZ, Cleary EJ, Brummett RE.

J Acoust Soc Am. 1979 Dec;66(6):1713-8.

PMID:
521555
38.

Quantitative relationships of the ototoxic interaction of kanamycin and ethacrynic acid.

Brummett RE, Brown RT, Himes DL.

Arch Otolaryngol. 1979 May;105(5):240-6.

PMID:
435146
41.

[Comparative ototoxicity of aminoglycoside antibiotics in a guinea pig model (author's transl)].

Brummett RE.

Nouv Presse Med. 1978 Nov 29;7(42):3849-53. French.

PMID:
568779
42.

Combined effects of noise and neomycin. Cochlear changes in the guinea pig.

Brown JJ, Brummett RE, Meikle MB, Vernon J.

Acta Otolaryngol. 1978 Nov-Dec;86(5-6):394-400.

PMID:
716862
43.

Comparative ototoxic liability of netilmicin and gentamicin.

Brummett RE, Fox KE, Brown RT, Himes DL.

Arch Otolaryngol. 1978 Oct;104(10):579-84.

PMID:
697635
44.

Ototoxicity of tobramycin, gentamicin, amikacin and sisomicin in the guinea pig.

Brummett RE, Fox KE, Bendrick TW, Himes DL.

J Antimicrob Chemother. 1978 May;4 Suppl A:73-83. No abstract available.

PMID:
659353
45.

The potentiation of noise-induced hearing loss by neomycin.

Vernon J, Brown J, Meikle M, Brummett RE.

Otolaryngology. 1978 Jan-Feb;86(1):ORL-123-4. No abstract available.

PMID:
114910
46.

Comparative ototoxicity of BB-K8 (amikacin), gentamicin, sisomicin and tobramycin in the guinea pig.

Brummett RE, Fox KE.

Proc West Pharmacol Soc. 1977;20:449-53. No abstract available.

PMID:
896854
47.

Detection of ototoxicity from drugs applied topically to the middle ear space.

Brummett RE, Harris RF, Lindgren JA.

Laryngoscope. 1976 Aug;86(8):1177-87.

PMID:
181649
48.

Tobramycin ototoxicity: a second look.

Brummett RE, Brown RT.

Arch Otolaryngol. 1975 Sep;101(9):540-3.

PMID:
1164236
49.

Cochlear damage resulting from kanamycin and furosemide.

Brummett RE, Traynor J, Brown R, Himes D.

Acta Otolaryngol. 1975 Jul-Aug;80(1-2):86-92.

PMID:
1166784
50.

Interaction of kanamycin and ethacrynic acid. Severe cochlear damage in guinea pigs.

West BA, Brummett RE, Himes DL.

Arch Otolaryngol. 1973 Jul;98(1):32-7. No abstract available.

PMID:
4713139

Supplemental Content

Loading ...
Support Center